首个治疗周期的信迪利单抗联用紫杉醇(白蛋白结合型)致急性肝衰竭1例  

A case of acute hepatic failure after the first treatment cycle of sintilimab combined with albumin-bound paclitaxel

作　　者：吴玉佩 邱志宏[1] 郭少伟 王泽普[3] 赫立恩[1] 尹岳松 高飞[2] 吴茵[1] WU Yupei;QIU Zhihong;GUO Shaowei;WANG Zepu;HE Lien;YIN Yuesong;GAO Fei;WU Yin(Department of Pharmacy/Hebei Key Laboratory of Clinical Pharmacy,Hebei General Hospital,Hebei Shijiazhuang 050051,China;Department of Oncology,Hebei General Hospital,Hebei Shijiazhuang 050051,China;Department of Hepato-Biliary-Pancreatic Surgery,Hebei General Hospital,Hebei Shijiazhuang 050051,China)

机构地区：[1]河北省人民医院,药学部/河北省临床药学重点实验室,河北石家庄050051 [2]河北省人民医院,肿瘤科,河北石家庄050051 [3]河北省人民医院,肝胆胰外科,河北石家庄050051

出　　处：《中国医院药学杂志》2025年第5期601-603,共3页Chinese Journal of Hospital Pharmacy

摘　　要：免疫检查点抑制剂联合化疗是晚期非小细胞肺癌的一线治疗方案,可以延长患者生存期。该研究报道1例信迪利单抗联合紫杉醇(白蛋白结合型)首个治疗周期后发生急性肝衰竭致患者死亡的病例,分析其发生过程、相关性、治疗措施和死亡原因,以提高医护人员对该治疗方案安全性的认识。The combination of immune checkpoint inhibi⁃tors and chemotherapy is the first-line treatment for advanced non-small cell lung cancer that prolongs the survival.In this study,we reported a case of acute hepatic failure resulting in death after the first cycle of sintilimab combined with albumin-bound paclitaxel,and analyzed the process,relevance,treat⁃ment and cause of death,so as to improve the awareness of the safety of this treatment program.

关 键 词：免疫检查点抑制 信迪利单抗 化疗药物 紫杉醇 肝功能衰竭 

分 类 号：R979.1[医药卫生—药品]